Hal Barron, GSK R&D chief, at Endpoints News' UKBIO 2019

Glax­o­SmithK­line, Vir look to suc­ceed where Lil­ly failed with NIH an­ti­body study in hos­pi­tal­ized Covid-19 pa­tients

In the hunt for an ef­fec­tive Covid-19 ther­a­py, mon­o­clon­al an­ti­bod­ies have turned up mixed da­ta so far. Eli Lil­ly was Ex­hib­it A in Oc­to­ber when the NIH quick­ly cut its an­ti­body from a tri­al in mod­er­ate­ly ill hos­pi­tal­ized pa­tients. But now, Glax­o­SmithK­line and part­ner Vir Biotech­nol­o­gy are hop­ing to suc­ceed where Lil­ly failed.

Af­ter Lil­ly’s sting­ing loss in achiev­ing sus­tained re­cov­ery in hos­pi­tal­ized Covid-19 pa­tients treat­ed with its an­ti­body, Glax­o­SmithK­line and Vir will now take a shot at that pop­u­la­tion as part of a place­bo-con­trolled sub­tri­al in the NIH’s “mas­ter pro­to­col” Ac­tiv-3.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.